4D Molecular Therapeutics, Inc.
Company Stats
- Market Cap
- $790.5M
- as of Sep 30, 2026
- Shares Outstanding
- 55.2M
- Free Float
- 76.1%
Income Statement
- Revenue
- $85.2M
- Operating Income
- -$159.5M
- Net Income
- -$140.1M
- EBITDA
- -$154.3M
- Revenue Growth, 3Y
- 200.9%
- FCF Margin, 3Y Avg
- -124827.8%
- FCF Margin, Worst Year
- -373975.7%
Cash Flow
- Free Cash Flow
- -$109.6M
- FCF Yield
- -13.9%
- Owner FCF Yield
- -16.7%
Balance Sheet
- Cash & Equivalents
- $60.2M
Returns & Capital
- SBC, 3Y Avg
- $22.6M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $85.2M | -$109.6M | -128.6% |
| FY2024 | $37,000 | -$138.4M | -373975.7% |
| FY2023 | $20.7M | -$78.6M | -379.1% |
| FY2022 | $3.1M | -$98.2M | -3139.1% |
| FY2021 | $18.0M | -$78.2M | -433.8% |
Annual filing data through FY ended December 31, 2025; shares and float as of November 3, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges